Skip to search formSkip to main contentSkip to account menu

PEDIARIX

National Institutes of Health

Related topics

Related topics

7 relations

Broader (7)

Diphtheria-Tetanus-(whole-cell) Pertussis VaccineHepatitis B Surface Antigen VaccineHepatitis B VaccinesPoliovirus Vaccine, Inactivated

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
The relationship between pediatric combination vaccines and market effects.
We explored market factors that affect pediatric combination vaccine uptake in the US public-sector pediatric vaccine market. We… 
2013
2013
CDC issues guidance for Pentacel, Daptacel and Pediarix shortages
In response to reduced availability of the vaccines Pentacel, Daptacel and Pediarix, the Centers for Disease Control and… 
2011
2011
Financial Impact to Providers Using Pediatric Combination Vaccines
OBJECTIVE: To understand the financial impact to providers for using a combination vaccine (Pediarix [GlaxoSmithKline Biologicals… 
Review
2009
Review
2009
Kawasaki Disease After Vaccination: Reports to the Vaccine Adverse Event Reporting System 1990–2007
Background: Kawasaki disease (KD) is a multisystemic vasculitis primarily affecting children <5 years. A review of RotaTeq… 
2003
2003
Pediarix--a combined vaccine for infants.
2003
2003
FDA licensure of diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), and poliovirus vaccine combined, (PEDIARIX) for use in infants.
  • MMWR. Morbidity and mortality weekly report
  • 2003
  • Corpus ID: 46068830
On December 13, 2002, the U.S. Food and Drug Administration (FDA) licensed a combined diphtheria and tetanus toxoids and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)